Trinity Biotech received WHO approval for offshored, outsources manufacturing

Trinity Biotech (TRIB) announced it has received World Health Organization, WHO, approval for the offshored and outsourced upstream manufacturing activities of its high-volume TrinScreen HIV rapid test, a cornerstone diagnostic product used in HIV screening programs. This regulatory approval marks a critical milestone in the Company’s comprehensive transformation plan aimed at restoring financial performance and driving sustainable profitability. This key regulatory approval enables Trinity Biotech to transition upstream production from its legacy in-house operations to a more cost-effective and scalable outsourced model, while maintaining the highest levels of product integrity and regulatory compliance.